Earlier studies on combined antibiotic action from this laboratory have resulted in the formulation of a scheme for combined antibiotic action.
Antibiotics have been divided tentatively into two groups: I. penicillin, streptomycin, bacitracin, and neomycin; II. chloramphenicol, aureomycin, terramycin (Jawetz and Gunnison, 1952a,b; Jawetz et al., 1952) . Mixtures of group I drugs often resulted in synergism, never in antagonism. Mixtures of group II drugs showed no combined effects beyond simple addition. Tue mixture of an antibiotic of group I with a drug of group II resulted in either synergism or antagonism apparently depending in part upon the sensitivity of the test bacteria to the group I drug. Thus, if the bacteria were highly sensitive to the group I antibiotic, the addition of a group II drug often interfered with the early bactericidal action of the first drug (antagonism). On the other hand, if the organisms were relatively resistant to the group I drug, in some instances the addition of a group II drug resulted in synergism, i.e., in a marked increase of early bactericidal action and the killing of greater numbers of bacteria than could be expected from simple summation of single drug effects. Most of the earlier tests were carried out with bacteria isolated from random clinical infections.
Since the relative susceptibility of microorganisms to group I drugs appeared to influence the observed end result of group I + group II combined antibiotic action, it was deemed important to compare the behavior of bacterial variants of graded resistance to group I drugs when exposed to group I + group II combinations. The present paper reports such a study. Bacteria were selected which were highly sensitive to group I drugs and which were killed more rapidly when exposed to a group I drug alone than when a group II drug was added. Resistant variants were obtained then from these cultures and subjected to tests with antibiotics singly and in combination. It was thought possible that although a given pair of group I + group II antibiotics acted antagonistically against the orinally sensitive culture they might act synergistically against the more resistant variants derived from it.
MODS AND MATERALS
Definition. "Synergism" in vitro has been defined as the ability of two drug to produce a marked increase in the bactericidal rate within the first 24 hours of exposure as compared with the rate with either drug alone and the killing of greater numbers of bacteria than could be expected from simple summation of single drug effects. The term "synergism" has been reserved for combined action unequivocally in exes of simple algebraic summnation, and the term "addition" has been used for other instances of positive summation. "Antagonism" in vitro has been defined as a marked decrease in the early bactericidal rate as compared with that of the more active single drug even though the combination after prolonged incubation may kill more organisms than either drug alone. These definitions have been chosen because they seem to correlate well with results in the treatment of experimental infections in mice and with certain clinical evidence (Jawets and Gunnison, 1952a,b (Szybalski and Bryson, 1952 (Gunnison et al., 1950b) .
RESULTS
The first organism studied, M. pyogenes var. albus, strain M, was killed rapidly by bacitracin in a concentration of 10 ,g per ml. A variant strain was obtained which was resistant to this concentration of bacitracin. The results of comparative tests of the resistant and sensitive strains exposed to bacitracin and terramycin alone and in combination are shown in figures 1 and 2. With the sensitive strain, the addition of terramycin (1 jug per ml) to bacitracin (10 ,ug per ml) resulted in antagonism; but with the resistant variant, the two drugs in these concentrations had an additive effect. This suggested that antagonism might be converted into synergism as the resistance of the culture to the group I drug increased. However, when a larger amount of bacitracin (100 ,ug per ml) was used which was bactericidal for the more resistant variant, the terramycin again reduced the rate of killing just as it had done with the sensitive strain at the lower level of bacitracin.
Six additional bacitracin resistant variants of this micrococcus with different degrees of resistance were tested. With those variants which were inhibited but not killed by a given dose of bacitracin, the combination of that dose with terramycin had an additive effect; with these which were rapidly killed by that dose of bacitracin, the combination had an antagonistic effect. Each variant was tested with bacteriostatic and bactericidal amounts of bacitracin alone and combined with terramycin. In each instance, terramycin showed addition when mixed with bacteriostatic doses of bacitracin but interfered with actively bactericidal doses.
In view of these results, the sensitive strain was tested further with a wide range of concentrations of bacitracin. Again it was found that static doses of bacitracin in a narrow range showed addition when combined with terramycin, whereas this group II drug interfered with bactericidal doses of bacitracin over a much wider range (figures 1 and 2 to penicillin . Eight variants at different levels of penicillin resistance were selected for the tests summarized in Another culture of M. pyogenes var. albus, strain L, and penicillin resistant variants derived from it were exposed to mixtures of penicillin and chloramphenicol with essentially the same results as those described above.
Streptococcw pyogenes, strain C203, was known to be highly sensitive to both penicillin and bacitracin. Terramycin had been shown to interfere with the activity of these group I drugs (Gunnison et al., 1950a; Speck et al., 1951 (Gunnison et al., 1950a; Jawetz et al., 1951a) . With the terramycin resistant variant, however, this drug no longer interfered with the action of streptomycin except for a slight, transitory antagonism when large, somewhat bacteriostatic doses of termmycin were used (100 ;&g per ml). This was not surprising because ineffective amounts of group II drugs never interfered with group I drugs. When terramycin was combined with penicillin, the results were less clear-cut as this terramycin resistant ml showed an additive effect in the presence of teramycin, whereas with the resistant strain 200 to 400 units were required to give this effect. Difficulty was encountered in obtaining streptomycin resistant strains which were not also streptomycin dependent, but a variant which was not dependent was isolated finally by the gradient plate method. This strain differed in behavior from the penicillin or bacitracin resistant variants of the organism tested thus far in that no antagonism could be demonstrated figure 2) . Here, the lower doses of streptomycin when combined with terramycin showed the usual additive effect. Above this range, however, there was a sharp end point where the streptomycin alone was rapidly bactericidal. There was no antagonism whatever between terramycin and any concentration of streptomycin. Although here, too, antagonism was not converted into synergism as resistance to the group I drug developed, in this instance the antagonism was completely obliterated; whereas with strains resistant to penicillin or bacitracin it merely occurred at higher drug levels.
In view of the results reported here, all of the original cultures previously studied (Jawets et al., 1952) were retested over a wider range of concentrations to see whether similar patterns of behavior were shown. In particular it was necessary to determine whether any of the instances which had been reported as "synergism" were merely examples of the additive effect of bacteriostatic amounts of group I drugs when combined with group II drugs which might be antagonistic when higher bactericidal doses of the group I drug were used. With all pairs of drugs previously designated as antagonistic when acting on a given organism, there was a narrow zone of concentrations of the group I antibiotic in which the effect was additive, whereas the group II drug always interfered with larger doses. On the other hand, with all pairs that previously had been designated as synergistic against a given organism there was an additive effect with all concentrations of group I drug over a wide range, including bactericidal amounts, and no interference at any level. Furthermore, in these synergistic systems the combination was more effective than 2 to 10 times the dose of either drug acting alone.
DISCUSSION
The aims and results of the work reported in this paper are restated in the following questions and answers:
(1) Can both synergism and antagonism be demonstrated with a given pair of drugs acting on a single strain of bacteria, depending upon the relative proportion of drugs in the mixture? In earlier papers in this series it was stated that synergism could not be converted into antagonism nor vice versa within a given test system by simply altering the proportion of drugs present. The quantitative data of the present work support this conclusion. An additional fact is brought out, however. When the whole range of concentrations of an "antagonistic" pair of drugs is studied, a narrow range often can be discovered within which the drugs are additive in their action. With resistant bacterial variants, the additive zone tends to be somewhat wider than with the original sensitive strains. This additive range occurs when both drugs are present in bacteriostatic quantities. The magnitude of additive action within this range of concentrations is often small so that the death rate of bacteria exposed to the combination of drugs usually does not equal, and rarely exceeds, the death rate obtained by doubling the concentration ofa single drug. While this effect does not fulfill the criteria for "synergism" used in our work, it well might account for the reports by others of both antagonistic and synergistic effects of a given drug pair against a single strain of microorganisms (Lankford and Lacy, 1949; Spicer, 1950; Bliss et al., 1952) .
The spectrum of combined action within a single "antagonistic" test system therefore may include the following consecutive zones as the concentration of the active, group I drug is raised progressively; (a) (Jawetz and Speck, 1950) but later had been discounted because of its extreme rarity.
In contrast to the ordinarily unilateral nature of antibiotic antagonism, synergism is a mutual phenomenon and has never been changed to antagonism by changing the relative concentrations of drugs. Only one of the members of a synergistic drug pair needs to exhibit a biological effect in the concentration entering into the combination (Jawetz, 1952 (Jawetz et al., 1951a,b; Speck et al., 1951; Ahern et al., 1952; Ercoli and Crminati, 1952; Lepper et al., 1952 ). An excess of either of the participating drugs frequently overcomes antagonism in vivo (Speck et al., 1951; Ahern et al., 1952) , and this has been demonstrated in vitro in some instances. With the highly drug sensitive organisms, against which antagonism is most likely, the drug excess obtained with ordinary doses in therapy must be large so that demonstrable antagonism would not be expected. With drug resistant bacteria, on the other hand, it is unlikely that sufficiently high, bactericidal levels could be reached in the tissues to permit antagonism. These points add to previously summarized evidence in minimizing the likelihood of observable antibiotic antagonism in clinical situations.
SUMMARY
Bacterial variants of graded antibiotic resistance were tested for their behavior toward antibiotic combinations in order to investigate the role played by resistance toward one agent in the response to a mixture of drugs. It was found that antibiotic antagonism with a certain drug pair acting on an antibiotic sensitive bacterial strain was not converted to synergism when the same drugs acted on an antibiotic resistant variant. The type of combined action, whether synergism, indifference, or antagonism, was essentially stable within a given test system although wide variations in drug concentration were necessary to demonstrate this action against bacteria of varying resistance.
When "antagonistic" drug pairs were subjected to a detailed study of dosage relationships, a narrow additive zone was found often. This occurred in the range of bacteriostatic concentrations of both drugs and never had the magnitude of true synergism. Synergistic test systems did not contain areas of antagonism. The relationship of these results to earlier work is discussed, and factors limiting the occurrence of antibiotic antagonism in animal and human infections are summarized.
